Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
作者： Mohamed Hebbar , Frédéric Di Fioré , Thierry Conroy , Claire Giraud , Laurent Gasnault
DOI: 10.1159/000127385
关键词:
摘要: Objective: To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Methods:
core.ac.uk
sci-hub.se 参考文章(26)
Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F
L Assersohn, A Norman, D Cunningham, T Benepal, P J Ross, J Oates, Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma British Journal of Cancer. ,vol. 79, pp. 1800- 1805 ,(1999) , 10.1038/SJ.BJC.6990287
C. Massacesi, A. Norman, T. Price, M. Hill, P. Ross, D. Cunningham, A clinical nomogram for predicting long-term survival in advanced colorectal cancer European Journal of Cancer. ,vol. 36, pp. 2044- 2052 ,(2000) , 10.1016/S0959-8049(00)00286-0
John Nemunaitis, John Cox, Wally Meyer, Alice Courtney, Gabriele Mues, Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). American Journal of Clinical Oncology. ,vol. 20, pp. 527- 529 ,(1997) , 10.1097/00000421-199710000-00020
Naureen Starling, David Cunningham, Cetuximab in Previously Treated Colorectal Cancer Clinical Colorectal Cancer. ,vol. 5, ,(2005) , 10.3816/CCC.2005.S.004
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
B Vincenzi, D Santini, C Rabitti, R Coppola, B Beomonte Zobel, L Trodella, G Tonini, Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. British Journal of Cancer. ,vol. 94, pp. 792- 797 ,(2006) , 10.1038/SJ.BJC.6603018
S. Anwar, I. M. Frayling, N. A. Scott, G. L. Carlson, Systematic review of genetic influences on the prognosis of colorectal cancer. British Journal of Surgery. ,vol. 91, pp. 1275- 1291 ,(2004) , 10.1002/BJS.4737
Caroline Robert, Jean-Charles Soria, Alain Spatz, Axel Le Cesne, David Malka, Patricia Pautier, Janine Wechsler, Catherine Lhomme, Bernard Escudier, Valérie Boige, Jean-Pierre Armand, Thierry Le Chevalier, Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncology. ,vol. 6, pp. 491- 500 ,(2005) , 10.1016/S1470-2045(05)70243-6